

Pylera[®] (bismuth subcitrate potassium/metronidazole/tetracycline) – First-time generic

- On March 10, 2023, [Par](#) launched an [AB-rated](#) generic version of AbbVie's [Pylera \(bismuth subcitrate potassium/metronidazole/tetracycline\)](#) capsules.
- Pylera is approved in combination with omeprazole for the treatment of patients with *Helicobacter pylori* (*H. pylori*) infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate *H. pylori*.
- Pylera carries a boxed warning for potential for carcinogenicity.
- According to IQVIA, Pylera had estimated annual sales of \$30 million in the U.S.